Tracking Cathie Wood: Increased position in fintech company Block by over 450,000 shares, while reducing holdings in some AI and genomics targets

On Monday, August 31, 2026, the three major US stock indices closed lower collectively. The S&P 500 fell 0.33% to 7,686.14 points, the Nasdaq dropped 0.12% to 26,370.89 points, and the Dow Jones Industrial Average saw the largest decline of 0.70%, closing at 53,185.90 points. On the last trading day of the month, overall market sentiment was cautious, with capital showing signs of rotation.

On that day, Cathie Wood increased positions against the trend in fintech, aerospace, and precision medicine, while trimming positions in several AI applications and genomics targets, reflecting a strategic intent of "portfolio rebalancing and structural adjustment."

Buy Side: Focusing on the long-term disruptive potential of fintech, aerospace, and gene editing

$Block (XYZ.US)$ Added 456,059 shares, making it the largest buy target of the day. Block’s Cash App continues to deepen its integration in the payment ecosystem and cryptocurrency infrastructure, which may align with ARK’s long-term bet on the rising penetration of decentralized finance.

$Rocket Lab (RKLB.US)$ Added 200,303 shares. As the commercial aerospace race accelerates, Rocket Lab’s frequency and cost advantages in the small satellite launch market are gradually becoming apparent. ARK’s move may be strengthening its core allocation to the new space economy.

$Guardant Health (GH.US)$ Added 56,987 shares. As a leader in liquid biopsy, Guardant Health continues to advance its commercialization path for early cancer screening, which may fit ARK’s deep investment logic in the precision medicine theme.

$Intellia Therapeutics (NTLA.US)$ Added 40,875 shares. In vivo gene editing technology is entering a critical period of clinical validation. If Intellia’s CRISPR therapy pipeline continues to produce positive data, the potential for valuation re-rating should not be overlooked.

$Circle (CRCL.US)$ Added 35,192 shares. As the issuer of the USDC stablecoin, Circle holds a unique position in crypto financial infrastructure. ARK’s purchase may reflect its expectation that commercialization will accelerate as the regulatory framework for stablecoins becomes clearer.

$Scribe Therapeutics (SCTX.US)$ Added 10,742 shares. Scribe focuses on the next-generation CRISPR-CasX technology platform, belonging to the frontier gene editing sector closely tracked by ARK. This increase may represent a continued effort to build a deep position in this niche area.

$Veracyte (VCYT.US)$ Added 7,031 shares. Veracyte’s genomic diagnostic technology has a moat in the precise typing of tumors such as thyroid cancer. ARK’s slight increase may be a minor adjustment or top-up within the precision medicine sector.

Sell Side: Rebalancing positions in AI applications, genomics, and e-commerce targets

$Personalis (PSNL.US)$ Reduced by 175,841 shares, marking the largest sell-off of the day. Personalis’s commercialization progress in cancer genomics sequencing may have fallen short of expectations, and ARK’s significant adjustment may reflect a reassessment of its short-term catalysts.

$Tempus AI (TEM.US)$ Reduced by 169,672 shares. Tempus AI holds substantial clinical data assets in the medical AI sector. This reduction may be part of month-end portfolio rebalancing, or it could reflect ARK's structural reallocation within the AI healthcare赛道.

$Palantir (PLTR.US)$ Reduced by 139,456 shares. Palantir's stock has seen significant cumulative gains year-to-date. This adjustment may reflect active management of portfolio concentration to free up capital for other priority targets.

$Shopify (SHOP.US)$ Reduced by 80,181 shares. Growth expectations in the e-commerce infrastructure sector may face marginally slowing pressure. ARK's reduction in Shopify may reflect its overall strategy to underweight internet platform assets.

$Roblox (RBLX.US)$ Reduced by 58,873 shares. The short-term commercialization path for the metaverse and interactive entertainment sectors remains uncertain. ARK may choose to moderately reduce the weight of such assets in its portfolio.

$10x Genomics (TXG.US)$ Reduced by 49,811 shares. Competition in the single-cell and spatial genomics instrument market is intensifying, putting pressure on 10x Genomics' profitability timeline. This reduction may signal ARK's risk reassessment of this target.

$Twist Bioscience (TWST.US)$ Reduced by 30,610 shares. The growth pace of upstream synthetic biology tool stocks may fall short of expectations. ARK's reduction may be a strategic adjustment within the broader genomics sector to weed out weaker performers and retain stronger ones.

$Advanced Micro Devices (AMD.US)$ Reduced by 8,623 shares, a relatively small scale. The competitive landscape for AMD in the AI accelerated computing market is still evolving. This slight reduction may be a routine minor position adjustment rather than a signal of a strategic shift.

Futubull [Opportunity Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity holdings, follow big investors' layouts with one click, precisely lock in high-quality targets, and invest with greater confidence!

252K Views